None listed
Conditions
Interventions
Intervention1: Face Cream- F 444-057: A pea size amount of the Face Cream applied on the full face twice per day for 2 weeks.
Control Intervention1: not applicable: not applicable
Sponsors
Kenvue Brands LLC.
Eligibility
Inclusion criteria
Inclusion criteria: a) Female b) 25 to 70 years old c) Fitzpatrick Skin Type III, IV, V, or VI d) More than 6 participants in IPL treatment group must undergone IPL and 6 participants in Microneedling group must undergone Microneedling treatment in the past 1-6 months before the study. e) Generally, in good health based on medical history reported by the trial participant. f) Able to read, write, speak, and understand English or Kannada. g) Willing to sign the Consent for Photograph Release. h) Intend to complete the study and is willing and able to follow all study instructions
Exclusion criteria
Exclusion criteria: a) Has known allergies or adverse reactions to common topical skincare product ingredients used in the investigational product or ancillary products or supplies such as latex or adhesives. b) Has undergone a facial peel, intense pulsed light treatment, microneedling, or any other professional facial treatment within 30 days prior to Visit 1. c) Has used a topical retinol treatment within 7 days prior to Visit 1. d) Presents with any skin condition that may confound study results, including but not limited to active skin infections, photosensitive disorders or use of photosensitizing medications, history of keloids, psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer. e) Has self reported Type 1 or Type 2 diabetes or is currently taking insulin or any other anti diabetic medication. f) Is taking any medication that may mask an adverse event or confound study results, including immunosuppressive or steroidal drugs within 2 months prior to Visit 1 or during the study, antihistamines within 2 weeks prior to Visit 1 or during the study, or non steroidal anti inflammatory drugs within 5 days prior to Visit 1 or during the study. Individuals taking these medications will not be considered eligible at screening. If a participant initiates any of these medications during the study, the Principal Investigator will be consulted to assess the impact on participant safety and study outcomes in accordance with concurrent or concomitant medication guidelines. g) Is self reported to be pregnant or planning to become pregnant during the study period. h) Has a history of or a concurrent medical or other condition that may place the individual at significant risk, confound study results, or significantly interfere with participation in the study. i) Is currently participating in another clinical study or has participated in any product use study within 30 days prior to Visit 1. j) Is an employee or contractor of the Principal Investigator, study site, or sponsor, or an immediate family member of any of these individuals.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the tolerability of an investigational face cream when used after a post POST INTENSE PULSED LIGHT (IPL) and/OR microneedling procedures in female trial participants.Timepoint: Day 0, Hour 48, Day 14 | — |
Secondary
| Measure | Time frame |
|---|---|
| noneTimepoint: none | — |
Countries
India
Contacts
Public ContactSudhanthiran S
[KENVUE],JNTL Consumer Health (India) Private Limited
Outcome results
None listed